Use este identificador para citar ou linkar para este item: http://higia.imip.org.br/handle/123456789/1048
Registro completo de metadados
Campo DCValorIdioma
dc.contributor.authorAndrade-Lima, Ana Luiza Magalhães de-
dc.contributor.authorLins, Mecneide Mendes-
dc.contributor.authorBorborema, Maria do Céu Diniz-
dc.contributor.authorMatos, Ana Paula Rodrigues-
dc.contributor.authorOliveira, Kaline Maria Maciel de-
dc.contributor.authorMello, Maria Júlia Gonçalves-
dc.date.accessioned2024-06-12T17:15:14Z-
dc.date.available2024-06-12T17:15:14Z-
dc.date.issued2023-
dc.identifier.urihttp://higia.imip.org.br/handle/123456789/1048-
dc.description.abstractObjective: The objective of this study was to evaluate the clinical evolution of coronavirus disease 2019 (COVID-19) in children and adolescents with cancer. Methods: Cohort involving patients undergoing cancer treatment, 19 years old and under, with the diagnosis of COVID-19 by real-time polymerase chain reaction, in a reference hospital, between March 2020 and November 2021. Data were collected from medical records and interviews with patients and/or guardians. The primary outcomes studied were severe/critical COVID-19 presentation, deaths from any cause and overall survival. The Cox proportional hazards multivariate regression analysis was performed to determine the risk of death. Results: Sixty-two participants were included, most (67.7%) were male, with a median age of 6.8 years. Severe/critical forms of COVID-19, observed in 24.2%, seemed to indicate that the pediatric population undergoing cancer treatment has a higher morbidity rate than the general pediatric population (8-9.2%). During follow-up (4.5-18 months), 20 patients (32.3%) completed their cancer treatment and 18 died (29%)-6 during hospitalization and 12 after discharge. In total 61.1% of deaths occurred within 63 days of a detectable real-time polymerase chain reaction. Patients with a higher risk of death presented with severe/critical COVID-19 [adjusted hazard risk (aHR): 8.51; 95% confidence interval (CI): 2.91-24.80; P < 0.00] solid tumors (aHR: 3.99; 95% CI: 1.43-11.12; P = 0.008) and diarrhea as a symptom of COVID-19 (aHR: 3.9; 95% CI: 1.23-12.73; P = 0.021). Conclusions: These findings support the impact that severe acute respiratory syndrome-associated coronavirus 2 infection has on the population of children and adolescents with cancer, not only regarding immediate severity but also in their survival rate. Further studies evaluating long-term outcomes of COVID-19 in children and adolescents with cancer should be encouraged.pt_BR
dc.language.isoenpt_BR
dc.subjectCOVID-19pt_BR
dc.subjectNeoplasiaspt_BR
dc.subjectSaúde da criançapt_BR
dc.titleThe infection profile and survival of children and adolescents with COVID-19 undergoing cancer treatment: a cohort study.pt_BR
dc.higia.programArtigos científicos colaboradores IMIPpt_BR
dc.higia.tipoArtigo Científicopt_BR
Aparece nas coleções:Artigos

Arquivos associados a este item:
Arquivo Descrição TamanhoFormato 
IMIP_Artigo - 017.2022-2023.pdf203.88 kBAdobe PDFVisualizar/Abrir


Os itens no repositório estão protegidos por copyright, com todos os direitos reservados, salvo quando é indicado o contrário.